References
- 1. GALUN D, BASARIC D, ZUVEALA M, BULAJIC P, BOGDANOVIC A, BIDZIC N, et al. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015 Sep 18;7(20):2274–2291.
- 2. EL-SERAG HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–1127.
- 3. WRZESINSKI SH, TADDEI TH, STRAZZABOSCO M. Systemic Therapy in Hepatocellular Carcinoma. Clin Liver Dis. 2011 May;15(2):423–41.
- 4. SUEANGOEN N, TANTIWETRUEANGDET A, PANVICHIAN R. HCC – derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci 2020 Mar;16:10:41.
- 5. BRUIX J, SHETMAN M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-1022.
- 6. WORNS MA, GALLE PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis 2010 Jul;42 Suppl 3:S302–9.
- 7. WHITTAKER S, MARAIS R, ZHU AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010 Sep;29(36):4989–5005.
- 8. SESHACHARYULU P, PONNUSAMY MP, HARIDAS D, JAIN M, GANTI AK, BATRA SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16(1):15–31.
- 9. KOMPOSCH K, SIBILIA M. EGFR Signaling in Liver Diseases. Int J Mol Sci 2016 Jan;17(1):30.
- 10. DIMIRI M, SATYANARAYANA A. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers 2020;12(2):491.
- 11. SU MC, LIEN HC, JENG YM. Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma. Cancer Lett 2005 Jun 16;224(1):117–121.
- 12. NIKOLOVA D, CHALOVSKA IVANOVA V, GENADIEVA DIMITROVA M, NIKOLOVSKA E, VOLKANOVSKA A, OROVCHANEC N, et al. Immunohistochemical expression of Epidermal Growth Factor Receptor in Hepatocellular Carcinoma. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2018 Dec 1;39(2–3):21–28.
- 13. NIKOLOVA D, CHALOVSKA IVANOVA V, GENADIEVA DIMITROVA M, JOVANOVIK R, KOSTADINOVA KUNOVSKA S, OROVCHANEC N, et al. Hepatocellular carcinoma clinicopathological characteristics, survival, and expression of various histologic molecular markers. Pol J Pathol 2019;70(4):269–276.
- 14. PORTOLANI N, CONIGLIO A, GHIDONI S, GIOVANELLI M, BENETTI A, TIBERIO GAM, et al. Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma. Prognostic and Therapeutic Implications. Ann Surg 2006 Feb;243(2):229–235.
- 15. HEIMBACH JK, KULIK LM, FINN RS, SIRLIN CB, ABECASSIS MM, ROBERTS LR, et al. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology 2018;67(1):358–380.
- 16. BELGHITI J, KIANMANESH R. Surgical treatment of hepatocellular carcinoma. HPB 2005; 7(1):42–49.
- 17. YEH CN, LEE WC, CHEN MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 2003;10:1070–6.
- 18. BERASAIN C, AVILA MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol 2014 Jan:49 (1):9–23.
- 19. BERASAIN C, PERUGORRIA MJ, LATESA MU, CASTILLO J, GONI S, SANTAMARIA M, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood). 2009;234:713–25.
- 20. LEE JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol 2015 Sep; 21(3):220–229.
- 21. ZHU AX, ROSMODRUC O, EVANS JTR, ROSS PJ, SANTORO A, CARRILHO FJ, et al. SEARCH: A Phase III, Randomized, Double-Blind,Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. J Clin Oncol 2015 Feb 20;33:559–566.